skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8102

Vascular Health and Risk Management

(2,748,412) Views

Editor in Chief Professor Roland Asmar

1178-2048


Acute coronary syndrome associated with Churg-Strauss syndrome
Annette Doris Wagner, Gerd Peter Meyer, Markus Rihl, Anke Rathmann, Ulrike Wittkop, et al
Vascular Health and Risk Management 2007, 3:775-779
21 November 2007


Emergency endovascular repair of acute descending thoracic aortic dissection
Muhammad Anees Sharif, Mark Edward O’Donnell, Paul Henry Blair, Peter Kennedy
Vascular Health and Risk Management 2007, 3:769-773
21 November 2007


Magnetic resonance imaging in coronary artery bypass surgery – improvement of global and segmental function in patients with severely compromized left ventricular function
Matthias Thielmann, Peter Hunold, Claudia Böhm, Parwis Massoudy, Heinz Jakob
Vascular Health and Risk Management 2007, 3:763-768
21 November 2007


Rates of symptom reoccurrence after endovascular therapy in subclavian artery stenosis and prevalence of subclavian artery stenosis prior to coronary artery bypass grafting
Brandon A Van Noord, Andrew H Lin, Jeffery J Cavendish
Vascular Health and Risk Management 2007, 3:759-762
21 November 2007


Is general anesthesia a risk for myocardium? Effect of anesthesia on myocardial function as assessed by cardiac troponin-i in two different groups (isofluran+N2O inhalation and propofol+fentanyl iv anesthesia)
Demet Dogan Erol, Ibrahim Ozen
Vascular Health and Risk Management 2007, 3:755-758
21 November 2007


Determinants of outcome in patients eligible for thrombolysis for ischemic stroke
Valeria Caso, Maurizio Paciaroni, Michele Venti, Francesco Palmerini, Giorgio Silvestrelli, et al
Vascular Health and Risk Management 2007, 3:749-754
21 November 2007


Macro- and micronutrients in patients with congestive heart failure, particularly African-Americans
Kevin P Newman, Syamal K Bhattacharya, Ahmad Munir, Richard C Davis, Judith E Soberman, et al
Vascular Health and Risk Management 2007, 3:743-747
20 November 2007


Colesevelam hydrochloride: reducing atherosclerotic coronary heart disease risk factors
Harold Bays, Peter H Jones
Vascular Health and Risk Management 2007, 3:733-742
20 November 2007


A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes
Mozhgan Dorkhan, Anders Frid
Vascular Health and Risk Management 2007, 3:721-731
20 November 2007


Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? The single pill of amlodipine/atorvastatin
FD Richard Hobbs
Vascular Health and Risk Management 2007, 3:711-719
20 November 2007


Management of intracerebral hemorrhage
Ramandeep Sahni, Jesse Weinberger
Vascular Health and Risk Management 2007, 3:701-709
20 November 2007


Utilizing enoxaparin in the management of STEMI
Andrea Rubboli, Alessandro Capecchi, Giuseppe Di Pasquale
Vascular Health and Risk Management 2007, 3:691-700
20 November 2007


Optimizing combination treatment in the management of type 2 diabetes
Giuseppe Derosa, Salvadeo Sibilla
Vascular Health and Risk Management 2007, 3:665-671
20 November 2007


Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann’s thrombasthenia
Man-Chiu Poon
Vascular Health and Risk Management 2007, 3:655-664
20 November 2007


Nebivolol in the treatment of chronic heart failure
Angie Veverka, Jennifer L Salinas
Vascular Health and Risk Management 2007, 3:647-654
20 November 2007


A critical review of anti-adrenergic therapy in patients with heart failure and diabetes mellitus
WH Wilson Tang
Vascular Health and Risk Management 2007, 3:639-645
20 November 2007


Ischemic preconditioning: Protection against myocardial necrosis and apoptosis
Efstathios K Iliodromitis, Antigone Lazou, Dimitrios Th Kremastinos
Vascular Health and Risk Management 2007, 3:629-637
20 November 2007


Cholesterol lowering for secondary prevention: What statin dose should we use?
Kiranbir Josan, Finlay A McAlister
Vascular Health and Risk Management 2007, 3:615-627
20 November 2007


Are pleiotropic effects of statins real?
Alberto Corsini, Nicola Ferri, Michele Cortellaro
Vascular Health and Risk Management 2007, 3:611-613
20 November 2007


Aldosterone antagonism in heart failure
Alan B Miller
Vascular Health and Risk Management 2007, 3:605-609
20 November 2007


Comprehensive cardiovascular risk management – what does it mean in practice?
Leif Erhardt, Robert Moller, Juan García Puig
Vascular Health and Risk Management 2007, 3:587-603
20 November 2007


Calcium channel blockers, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors: Effectiveness in combination with diuretics or β-blockers for treating hypertension
John D Bisognano, Trent McLaughlin, Craig S Roberts, Simon SK Tang
Vascular Health and Risk Management 2007, 3:579-585
20 November 2007


The role of HMG-CoA reductase inhibition in endothelial dysfunction and inflammation
Paolo Gelosa, Mauro Cimino, Alice Pignieri, Elena Tremoli, Uliano Guerrini, et al
Vascular Health and Risk Management 2007, 3:567-577
20 November 2007


Anti-hemophilic factor (recombinant), plasma/albumin-free method (octocog-alpha; ADVATE®) in the management of hemophilia A
Amy D Shapiro
Vascular Health and Risk Management 2007, 3:555-565
20 November 2007


ISVH Society September Newsletter
 
Vascular Health and Risk Management 2007, 3:0-0
21 November 2007

  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University